Drugs / Octocrylene
Octocrylene
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ANTHELIOS SX | — | 2006-07-21 | fda.gov ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT05736224 | May → Sep 2023 | skin cancer | Yale University | Completed | Met primary |
| Phase 1 | NCT03582215 | Jul 2018 → Feb 2019 | skin sensitivity to sun | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00530387 | Jul 2008 → Jul 2011 | photoallergic dermatitis | NHS Tayside | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Octocrylene | “The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and...” NCT05736224 ↗2“Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule” NCT03582215 ↗ “Octocrylene” NCT00530387 ↗ |
| Known as | NSC-760433 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201147 ↗ |
| Known as | Octocrilene | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201147 ↗ |
| Known as | Octocrileno | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201147 ↗ |
| Known as | Octocrylene component of anthelios sx | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201147 ↗ |
| Known as | Octocrylene component of capital soleil | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201147 ↗ |
| Modality | Small molecule | — CHEMBL1201147 ↗ |